| Literature DB >> 26850121 |
Maija Dambrova1, Marina Makrecka-Kuka2, Reinis Vilskersts3, Elina Makarova2, Janis Kuka2, Edgars Liepinsh2.
Abstract
Meldonium (mildronate; 3-(2,2,2-trimethylhydrazinium)propionate; THP; MET-88) is a clinically used cardioprotective drug, which mechanism of action is based on the regulation of energy metabolism pathways through l-carnitine lowering effect. l-Carnitine biosynthesis enzyme γ-butyrobetaine hydroxylase and carnitine/organic cation transporter type 2 (OCTN2) are the main known drug targets of meldonium, and through inhibition of these activities meldonium induces adaptive changes in the cellular energy homeostasis. Since l-carnitine is involved in the metabolism of fatty acids, the decline in its levels stimulates glucose metabolism and decreases concentrations of l-carnitine related metabolites, such as long-chain acylcarnitines and trimethylamine-N-oxide. Here, we briefly reviewed the pharmacological effects and mechanisms of meldonium in treatment of heart failure, myocardial infarction, arrhythmia, atherosclerosis and diabetes.Entities:
Keywords: Cardioprotective; Long-chain acylcarnitines; Meldonium; Trimethylamine-N-oxide; l-Carnitine
Mesh:
Substances:
Year: 2016 PMID: 26850121 DOI: 10.1016/j.phrs.2016.01.019
Source DB: PubMed Journal: Pharmacol Res ISSN: 1043-6618 Impact factor: 7.658